Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 76836-76838 [2013-30185]
Download as PDF
76836
Federal Register / Vol. 78, No. 244 / Thursday, December 19, 2013 / Notices
consortium member also receives or has
received funding from ANA.
• Whether the project provides
couples or family counseling activities
that are medically-based.
• Whether the project originated and
was designed by consultants, who have
provided a major role for themselves in
the performance of the project, and who
are not members of the applicant
organization, tribe, or village.
3. Scoring Guidance: ANA proposes
• Whether the project contains
to provide guidance to reviewers to
contingent activities that may impede,
utilize the table below when allocating
or indefinitely delay, the progress of the
points for applications in order to
project.
ensure consistency and equivalence in
the scoring among different panels and
• Whether the project has the
panel reviewers. ANA proposes to add
potential to cause unintended harm to
the following table to all FY14 FOAs:
participants, or that could negatively
impact the safety or privacy of
Excellent .......................................
93–100 individuals.
Very Good ....................................
86–92
• Whether the project may be used for
Good .............................................
78–85
Fair ................................................
70–77 the purpose of providing loan capital.
Needs Significant Improvement ...
0–69 Federal funds awarded under this FOA
may not be used for the purpose of
providing loan capital. This restriction
L. ANA Internal Review of Proposed
is not related to loan capital authorized
Projects: ANA proposes to clarify the
under Sec. 803A of NAPA [42 U.S.C.
language in Section V.2. Review and
2991b-1(a)(1)] for the purpose of the
Selection Process of the FOAs to clarify
Hawaiian Revolving Loan fund.
of the scope of ANA’s discretion to be
• Whether the project includes
exercised in making funding decisions
human subject research as defined at 45
as follows:
CFR 45.102 (d) and (f).
Based on the ranked order of
applications, ANA staff will perform an
• Whether the project is duplicative
internal review and analysis of the
of projects funded by other federal
applications ranked highest as a result
agencies.
of the panel’s review and scoring in
Please note: The funding restriction
order to determine the application’s
applied in prior years’ FOAs on ‘‘Projects
consistency with the purposes of NAPA, that seek to revive Native American
all relevant statutory and regulatory
languages that do not have any living
requirements, and the requirements of
speakers’’ has been removed from the above
the relevant FOA. ANA’s Commissioner list. Projects with this focus are now eligible
to receive funding under Language
has discretion to make all final funding
Preservation and EMI FOAs.
and award decisions. In the exercise of
such discretion the Commissioner will
M. Reporting: ANA proposes to
consider:
change the frequency of reporting
• Whether the project, as determined
requirements from quarterly to semibased on ANA’s administrative and
annual for the Objective Progress
programmatic expertise, does not to
Reports (OPR) and Financial Status
further the purpose of the funding
Reports (FSR). Therefore, grantees will
opportunity as described in Section I.
be required to submit an OPR and an
Funding Opportunity Description.
FSR every 6 months instead of every 3
• Whether the project is determined
months. Please note that grantees will
to be unlikely to be successful or cost
still be required to submit a Federal
effective based on the application
Financial Report—Federal Cash
submitted for evaluation in response to
Transaction Report SF–425 (FFR–FCTR)
Section IV.2. Project Description and
to the Division of Payment Management
Budget and Budget Justification.
(DPM) on a quarterly basis.
• Whether the project allows any one
Statutory Authority: This notice for public
community, or region, to receive a
comment is required by Section 814 of the
disproportionate share of the funds
Native American Programs Act of 1974
available for award.
(NAPA), as amended.
• Whether the projects is essentially
Lillian A. Sparks Robinson,
identical or similar in whole or in part
Commissioner, Administration for Native
to previously funded projects proposed
American.
by the same applicant or activities or
[FR Doc. 2013–30192 Filed 12–18–13; 8:45 am]
projects proposed by a consortium that
duplicate activities for which any
BILLING CODE 4184–34–P
emcdonald on DSK67QTVN1PROD with NOTICES
important to project monitoring and
success. For all FY14 FOAs, ANA
proposes to use the following criteria
values:
Need for Assistance—10 points;
Outcomes Expected—25 points;
Project Approach—30 points;
Objective Work Plan—25 points
Budget and Budget Justification—10
points
VerDate Mar<15>2010
16:41 Dec 18, 2013
Jkt 232001
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1619]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Current Good
Manufacturing Practice in
Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary
Supplements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (the PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
invites comments on the information
collection provisions of FDA’s
regulations regarding current good
manufacturing practice (CGMP) for
dietary supplements.
DATES: Submit either electronic or
written comments on the collection of
information by February 18, 2014.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
SUMMARY:
E:\FR\FM\19DEN1.SGM
19DEN1
Federal Register / Vol. 78, No. 244 / Thursday, December 19, 2013 / Notices
emcdonald on DSK67QTVN1PROD with NOTICES
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Current Good Manufacturing Practice
in Manufacturing, Packaging, Labeling,
or Holding Operations for Dietary
Supplements—21 CFR Part 111 (OMB
Control Number 0910–0606)—Extension
On October 25, 1994, the Dietary
Supplement Health and Education Act
(DSHEA) (Pub. L. 103–417) was signed
into law. DSHEA, among other things,
amended the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) by adding
section 402(g) of the FD&C Act (21
U.S.C. 342(g)). Section 402(g)(2) of the
FD&C Act provides, in part, that the
Secretary of Health and Human Services
may, by regulation, prescribe good
manufacturing practices for dietary
supplements. Section 402(g) of the
FD&C Act also stipulates that such
regulations will be modeled after CGMP
regulations for food and may not impose
standards for which there are no
current, and generally available,
analytical methodology. Section
402(g)(1) of the FD&C Act states that a
dietary supplement is adulterated if ‘‘it
has been prepared, packed, or held
under conditions that do not meet
current good manufacturing practice
regulations.’’ Under section 701(a) of the
FD&C Act (21 U.S.C. 371), FDA may
issue regulations necessary for the
efficient enforcement of the FD&C Act.
In the Federal Register of June 25, 2007
(72 FR 34752) (the June 25, 2007, final
VerDate Mar<15>2010
16:41 Dec 18, 2013
Jkt 232001
rule), FDA published a final rule that
established, in part 111 (21 CFR part
111), the minimum CGMP necessary for
activities related to manufacturing,
packaging, labeling, or holding dietary
supplements to ensure the quality of the
dietary supplement.
Records are an indispensable
component of CGMP. The records
required by FDA’s regulations in part
111 provide the foundation for the
planning, control, and improvement
processes that constitute a quality
control system. Implementation of these
processes in a manufacturing operation
serves as the backbone to CGMP. The
records show what is to be
manufactured; what was, in fact,
manufactured; and whether the controls
that the manufacturer put in place to
ensure the identity, purity, strength, and
composition and limits on contaminants
and to prevent adulteration were
effective. Further, records will show
whether and what deviations from
control processes occurred, facilitate
evaluation and corrective action
concerning these deviations (including,
where necessary, whether associated
batches of product should be recalled
from the marketplace), and enable a
manufacturer to assure that the
corrective action was effective. In
addition, by establishing recordkeeping
requirements, FDA can ensure that
industry follows CGMP during
manufacturing, packaging, labeling, or
holding operations. The regulations in
part 111 establish the minimum
manufacturing practices necessary to
ensure that dietary supplements are
manufactured, packaged, labeled, or
held in a manner that will ensure the
quality of the dietary supplements
during manufacturing, packaging,
labeling or holding operations.
The recordkeeping requirements of
the regulations include establishing
written procedures and maintaining
records pertaining to: (1) Personnel; (2)
sanitation; (3) calibration of instruments
and controls; (4) calibration, inspection,
or checks of automated, mechanical, or
electronic equipment; (5) maintaining,
cleaning, and sanitizing equipment and
utensils and other contact surfaces; (6)
water used that may become a
component of the dietary supplement;
(7) production and process controls; (8)
quality control; (9) components,
packaging, labels and product received
for packaging and labeling; (10) master
manufacturing and batch production;
(11) laboratory operations; (12)
manufacturing operations; (13)
packaging and labeling operations; (14)
holding and distributing operations; (15)
returned dietary supplements; and (16)
product complaints.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
76837
Description of Respondents:
Manufacturers, dietary supplement
manufacturers, packagers and
repackagers, labelers and re-labelers,
holders, distributors, warehousers,
exporters, importers, large businesses,
and small businesses engaged in the
dietary supplement industry.
The recordkeeping requirements of
the regulations in part 111 are set forth
in each subpart. In Table 1 of this
document we list the annual burdens
associated with recordkeeping, as
described in the June 25, 2007, final
rule. For some provisions listed in Table
1, we did not estimate the number of
records per recordkeeper because
recordkeeping occasions consist of
frequent brief entries of dates,
temperatures, monitoring results, or
documentation that specific actions
were taken. Information might be
recorded a few times a day, week, or
month. When the records burden
involves frequent brief entries, we
entered 1 as the default for the number
of records per recordkeeper. For
example, many of the records listed
under § 111.35 in Table 1, such as
§ 111.35(b)(2) (documentation, in
individual equipment logs, of the date
of the use, maintenance, cleaning, and
sanitizing of equipment), involve many
short sporadic entries over the course of
the year, varying across equipment and
plants in the industry. We did not
attempt to estimate the actual number of
recordkeeping occasions for these
provisions, but instead entered an
estimate of the average number of hours
per year. We entered the default value
of 1 as the number of records per
recordkeeper for these and similar
provisions. For § 111.35, the entry for
number of records is 1 as a default
representing a large number of brief
recordkeeping occasions.
In many rows of Table 1 of this
document, we list a burden under a
single provision that covers the written
procedures or records described in
several provisions. For example, the
burden of the batch production records
listed in Table 1 under § 111.260
includes the burden for records listed
under § 111.255 because the batch
production records must include those
records.
The number of records for batch
production records (and other records
kept on a batch basis in Table 1 of this
document) equals the annual number of
batches. The estimated burden for
records kept by batch includes both
records kept for every batch and records
kept for some but not all batches. We
use the annual number of batches as the
number of records that will not
necessarily be kept for every batch, such
E:\FR\FM\19DEN1.SGM
19DEN1
76838
Federal Register / Vol. 78, No. 244 / Thursday, December 19, 2013 / Notices
as test results or material review and
disposition records, because such
records are part of records, if they are
necessary, that will be kept for every
batch.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
21 CFR Section
111.14, records of personnel practices, including documentation of training .........................................................
111.23, records of physical plant sanitation practices, including pest control and water quality .............................
111.35, records of equipment and utensils calibration and
sanitation practices ...........................................................
111.95, records of production and process control systems
111.140, records that quality control personnel must make
and keep ...........................................................................
111.180, records associated with components, packaging,
labels, and product received for packaging and labeling
as a dietary supplement ...................................................
111.210, requirements for what the master manufacturing
record must include ..........................................................
111.260, requirements for what the batch record must include .................................................................................
111.325, records that quality control personnel must make
and keep for laboratory operations ..................................
111.375, records of the written procedures established for
manufacturing operations .................................................
111.430, records of the written procedures for packaging
and labeling operations ....................................................
111.475, records of product distribution and procedures
for holding and distributing operations .............................
111.535, records for returned dietary supplements ............
111.570, records regarding product complaints ..................
Total ..............................................................................
emcdonald on DSK67QTVN1PROD with NOTICES
1 There
Number of
records per
recordkeeper
Total annual
records
Avg. burden
per recordkeeping
Total hours
15,000
4
60,000
1
60,000
15,000
1
15,000
0.2
3,000
400
250
1
1
400
250
12.5
45
5,000
11,250
240
1163
279,120
1
279,120
240
1163
279,120
1
279,120
240
1
240
2.5
600
145
1408
204,160
1
204,160
120
1
120
15
1,800
260
1
260
2
520
50
1
50
12.6
630
15,000
110
240
1
4
600
15,000
440
144,000
0.4
13.5
0.5
6,000
5,940
72,000
........................
........................
........................
........................
929,140
are no capital costs or operating and maintenance costs associated with this collection of information.
The average burden per recordkeeping
estimates in Table 1 of this document
are based on those in the June 25, 2007,
final rule, which were based on our
institutional experience with other
CGMP requirements and on data
provided by Research Triangle Institute
in the ‘‘Survey of Manufacturing
Practices in the Dietary Supplement
Industry’’ cited in that rule.
The estimates in Table 1 of the
number of firms affected by each
provision of part 111 are based on the
percentage of manufacturers, packagers,
labelers, holders, distributors, and
warehousers that reported in the survey
that they have not established written
SOPs or do not maintain records that
were later required by the June 25, 2007,
final rule. Because we do not have
survey results for general warehouses,
we entered the approximate number of
facilities in that category for those
provisions covering general facilities.
For the dietary supplement industry, the
survey estimated that 1,460 firms would
be covered by the final rule, including
manufacturers, packagers, labelers,
holders, distributors, and warehousers.
The time estimates include the burden
involved in documenting that certain
VerDate Mar<15>2010
16:41 Dec 18, 2013
Jkt 232001
requirements are performed and in
recordkeeping. We used an estimated
annual batch production of 1,408
batches per year to estimate the burden
of requirements that are related to the
number of batches produced annually,
such as § 111.260, ‘‘What must the batch
production record include?’’ The
estimate of 1,408 batches per year is
near the midpoint of the number of
annual batches reported by survey
firms.
The length of time that CGMP records
must be maintained is set forth in
§ 111.605. Table 1 of this document
reflects the estimated burdens for
written procedures, record maintenance,
periodically reviewing records to
determine if they may be discarded, and
for any associated documentation for
that activity for records that are required
under part 111. We have not included
a separate estimate of burden for those
sections that require maintaining
records in accordance with § 111.605,
but have included those burdens under
specific provisions for keeping records.
For example, § 111.255(a) requires that
the batch production records be
prepared every time a batch is
manufactured, and § 111.255(d) requires
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
that batch production records be kept in
accordance with § 111.605. The
estimated burdens for both § 111.255(a)
and (d) are included under § 111.260
(what the batch record must include).
Dated: December 13, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–30185 Filed 12–18–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1588]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Tobacco Products,
Exemptions From Substantial
Equivalence Requirements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
SUMMARY:
E:\FR\FM\19DEN1.SGM
19DEN1
Agencies
[Federal Register Volume 78, Number 244 (Thursday, December 19, 2013)]
[Notices]
[Pages 76836-76838]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-30185]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1619]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Current Good Manufacturing Practice in Manufacturing,
Packaging, Labeling, or Holding Operations for Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice invites comments on the information collection
provisions of FDA's regulations regarding current good manufacturing
practice (CGMP) for dietary supplements.
DATES: Submit either electronic or written comments on the collection
of information by February 18, 2014.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or
[[Page 76837]]
provide information to a third party. Section 3506(c)(2)(A) of the PRA
(44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day
notice in the Federal Register concerning each proposed collection of
information, including each proposed extension of an existing
collection of information, before submitting the collection to OMB for
approval. To comply with this requirement, FDA is publishing notice of
the proposed collection of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements--21 CFR Part
111 (OMB Control Number 0910-0606)--Extension
On October 25, 1994, the Dietary Supplement Health and Education
Act (DSHEA) (Pub. L. 103-417) was signed into law. DSHEA, among other
things, amended the Federal Food, Drug, and Cosmetic Act (the FD&C Act)
by adding section 402(g) of the FD&C Act (21 U.S.C. 342(g)). Section
402(g)(2) of the FD&C Act provides, in part, that the Secretary of
Health and Human Services may, by regulation, prescribe good
manufacturing practices for dietary supplements. Section 402(g) of the
FD&C Act also stipulates that such regulations will be modeled after
CGMP regulations for food and may not impose standards for which there
are no current, and generally available, analytical methodology.
Section 402(g)(1) of the FD&C Act states that a dietary supplement is
adulterated if ``it has been prepared, packed, or held under conditions
that do not meet current good manufacturing practice regulations.''
Under section 701(a) of the FD&C Act (21 U.S.C. 371), FDA may issue
regulations necessary for the efficient enforcement of the FD&C Act. In
the Federal Register of June 25, 2007 (72 FR 34752) (the June 25, 2007,
final rule), FDA published a final rule that established, in part 111
(21 CFR part 111), the minimum CGMP necessary for activities related to
manufacturing, packaging, labeling, or holding dietary supplements to
ensure the quality of the dietary supplement.
Records are an indispensable component of CGMP. The records
required by FDA's regulations in part 111 provide the foundation for
the planning, control, and improvement processes that constitute a
quality control system. Implementation of these processes in a
manufacturing operation serves as the backbone to CGMP. The records
show what is to be manufactured; what was, in fact, manufactured; and
whether the controls that the manufacturer put in place to ensure the
identity, purity, strength, and composition and limits on contaminants
and to prevent adulteration were effective. Further, records will show
whether and what deviations from control processes occurred, facilitate
evaluation and corrective action concerning these deviations
(including, where necessary, whether associated batches of product
should be recalled from the marketplace), and enable a manufacturer to
assure that the corrective action was effective. In addition, by
establishing recordkeeping requirements, FDA can ensure that industry
follows CGMP during manufacturing, packaging, labeling, or holding
operations. The regulations in part 111 establish the minimum
manufacturing practices necessary to ensure that dietary supplements
are manufactured, packaged, labeled, or held in a manner that will
ensure the quality of the dietary supplements during manufacturing,
packaging, labeling or holding operations.
The recordkeeping requirements of the regulations include
establishing written procedures and maintaining records pertaining to:
(1) Personnel; (2) sanitation; (3) calibration of instruments and
controls; (4) calibration, inspection, or checks of automated,
mechanical, or electronic equipment; (5) maintaining, cleaning, and
sanitizing equipment and utensils and other contact surfaces; (6) water
used that may become a component of the dietary supplement; (7)
production and process controls; (8) quality control; (9) components,
packaging, labels and product received for packaging and labeling; (10)
master manufacturing and batch production; (11) laboratory operations;
(12) manufacturing operations; (13) packaging and labeling operations;
(14) holding and distributing operations; (15) returned dietary
supplements; and (16) product complaints.
Description of Respondents: Manufacturers, dietary supplement
manufacturers, packagers and repackagers, labelers and re-labelers,
holders, distributors, warehousers, exporters, importers, large
businesses, and small businesses engaged in the dietary supplement
industry.
The recordkeeping requirements of the regulations in part 111 are
set forth in each subpart. In Table 1 of this document we list the
annual burdens associated with recordkeeping, as described in the June
25, 2007, final rule. For some provisions listed in Table 1, we did not
estimate the number of records per recordkeeper because recordkeeping
occasions consist of frequent brief entries of dates, temperatures,
monitoring results, or documentation that specific actions were taken.
Information might be recorded a few times a day, week, or month. When
the records burden involves frequent brief entries, we entered 1 as the
default for the number of records per recordkeeper. For example, many
of the records listed under Sec. 111.35 in Table 1, such as Sec.
111.35(b)(2) (documentation, in individual equipment logs, of the date
of the use, maintenance, cleaning, and sanitizing of equipment),
involve many short sporadic entries over the course of the year,
varying across equipment and plants in the industry. We did not attempt
to estimate the actual number of recordkeeping occasions for these
provisions, but instead entered an estimate of the average number of
hours per year. We entered the default value of 1 as the number of
records per recordkeeper for these and similar provisions. For Sec.
111.35, the entry for number of records is 1 as a default representing
a large number of brief recordkeeping occasions.
In many rows of Table 1 of this document, we list a burden under a
single provision that covers the written procedures or records
described in several provisions. For example, the burden of the batch
production records listed in Table 1 under Sec. 111.260 includes the
burden for records listed under Sec. 111.255 because the batch
production records must include those records.
The number of records for batch production records (and other
records kept on a batch basis in Table 1 of this document) equals the
annual number of batches. The estimated burden for records kept by
batch includes both records kept for every batch and records kept for
some but not all batches. We use the annual number of batches as the
number of records that will not necessarily be kept for every batch,
such
[[Page 76838]]
as test results or material review and disposition records, because
such records are part of records, if they are necessary, that will be
kept for every batch.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Avg. burden
21 CFR Section Number of records per Total annual per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
111.14, records of personnel 15,000 4 60,000 1 60,000
practices, including
documentation of training......
111.23, records of physical 15,000 1 15,000 0.2 3,000
plant sanitation practices,
including pest control and
water quality..................
111.35, records of equipment and 400 1 400 12.5 5,000
utensils calibration and
sanitation practices...........
111.95, records of production 250 1 250 45 11,250
and process control systems....
111.140, records that quality 240 1163 279,120 1 279,120
control personnel must make and
keep...........................
111.180, records associated with 240 1163 279,120 1 279,120
components, packaging, labels,
and product received for
packaging and labeling as a
dietary supplement.............
111.210, requirements for what 240 1 240 2.5 600
the master manufacturing record
must include...................
111.260, requirements for what 145 1408 204,160 1 204,160
the batch record must include..
111.325, records that quality 120 1 120 15 1,800
control personnel must make and
keep for laboratory operations.
111.375, records of the written 260 1 260 2 520
procedures established for
manufacturing operations.......
111.430, records of the written 50 1 50 12.6 630
procedures for packaging and
labeling operations............
111.475, records of product 15,000 1 15,000 0.4 6,000
distribution and procedures for
holding and distributing
operations.....................
111.535, records for returned 110 4 440 13.5 5,940
dietary supplements............
111.570, records regarding 240 600 144,000 0.5 72,000
product complaints.............
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 929,140
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The average burden per recordkeeping estimates in Table 1 of this
document are based on those in the June 25, 2007, final rule, which
were based on our institutional experience with other CGMP requirements
and on data provided by Research Triangle Institute in the ``Survey of
Manufacturing Practices in the Dietary Supplement Industry'' cited in
that rule.
The estimates in Table 1 of the number of firms affected by each
provision of part 111 are based on the percentage of manufacturers,
packagers, labelers, holders, distributors, and warehousers that
reported in the survey that they have not established written SOPs or
do not maintain records that were later required by the June 25, 2007,
final rule. Because we do not have survey results for general
warehouses, we entered the approximate number of facilities in that
category for those provisions covering general facilities. For the
dietary supplement industry, the survey estimated that 1,460 firms
would be covered by the final rule, including manufacturers, packagers,
labelers, holders, distributors, and warehousers. The time estimates
include the burden involved in documenting that certain requirements
are performed and in recordkeeping. We used an estimated annual batch
production of 1,408 batches per year to estimate the burden of
requirements that are related to the number of batches produced
annually, such as Sec. 111.260, ``What must the batch production
record include?'' The estimate of 1,408 batches per year is near the
midpoint of the number of annual batches reported by survey firms.
The length of time that CGMP records must be maintained is set
forth in Sec. 111.605. Table 1 of this document reflects the estimated
burdens for written procedures, record maintenance, periodically
reviewing records to determine if they may be discarded, and for any
associated documentation for that activity for records that are
required under part 111. We have not included a separate estimate of
burden for those sections that require maintaining records in
accordance with Sec. 111.605, but have included those burdens under
specific provisions for keeping records. For example, Sec. 111.255(a)
requires that the batch production records be prepared every time a
batch is manufactured, and Sec. 111.255(d) requires that batch
production records be kept in accordance with Sec. 111.605. The
estimated burdens for both Sec. 111.255(a) and (d) are included under
Sec. 111.260 (what the batch record must include).
Dated: December 13, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-30185 Filed 12-18-13; 8:45 am]
BILLING CODE 4160-01-P